MORE WATER INDUSTRY FEATURES

• In A Drought, Non-Revenue Water Is The Cheapest New Supply You Have

  Drought conditions force utilities to seek new water sources, yet reducing non-revenue water offers an immediate supply boost. Eliminating sample waste and targeting line flushing recovers fully treated water without expensive capital projects.

• 2,080 Hours: What Five Sensors Gave Back To One Utility

  Routine sensor maintenance silently drains utility workforce capacity through constant recalibration, reagent refills, and travel time. Transitioning to low-maintenance monitoring technology reclaims thousands of operator hours, allowing short-handed crews to focus on vital system infrastructure priorities.

• AMI Under The Microscope: Beaverton Water Division Answers Questions About Its AMI Transition

  Beaverton Water Division’s transition to Kamstrup AMI and acoustic leak detection is modernizing meter reading, reducing infrastructure costs, improving leak identification, and streamlining operations as deployment progresses.

• The Role Of Ozone In Municipal Water Treatment

  Discover why ozone, a powerful oxidant and sanitizer, has become a leading solution for addressing water quality challenges.

• Overcoming Excipient Risks And Challenges For Parenteral Formulations

  Excipients are essential to parenteral formulations, which help protect APIs, enhance stability, and ensure safety. Learn how strategic excipient selection can optimize drug performance and patient outcomes.

• A True PFAS Solution Is About More Than Removal

  Engineers and project managers must take a complete cradle-to-grave approach when considering which technologies to implement as well as which vendors to partner with for their PFAS solution.

• Timing And Data Are Critical To Winning BTD For Rare Disease Drugs

  Breakthrough Therapy designation (BTD) can accelerate rare disease drug development—but timing and evidence are everything. Learn how to position your program for FDA success.

• From Syringes To Wearables: Formulation's Impact

  High‑concentration biologic formulations for prefilled syringes and on‑body devices enable easier self‑administration, reduce treatment burden, boost adherence, and address complex formulation challenges.

• Municipal Water Treatment: A Look At The Advantages Of Performance Testing For Powdered Activated Carbon

  Evaluating Powdered Activated Carbon through site-specific performance testing allows water utilities to optimize chemical dosing based on real-world efficacy rather than upfront price, preventing costly operational strains and ensuring reliable contaminant removal.

• Bayesian Study Designs In Early-Phase Oncology Trials

  In response to insufficient traditional dose-escalation methods, regulatory initiatives like the FDA’s Project Optimus advocate for identifying optimal biological doses rather than relying solely on maximum tolerated doses (MTD).

• City Of Mesa Leverages Hybrid-Cloud Architecture To Drive Operational Efficiency At Their Water Resources Department

  Transitioning to a hybrid-cloud architecture allows municipal utilities to securely centralize operational data. This structure gives engineering teams and consultants safe, self-serve access to near real-time insights, streamlining regulatory reporting and optimizing chemical usage.

• AEC PFAS Removal System Reduces PFAS Contamination In New Jersey

  This case study demonstrates the effectiveness of a new technology for removing PFAS from well water to below the EPA’s detection limits.

• How Climate Change Is Reshaping Surface Water Treatment Plant Design

  Climate change is expanding source water variability beyond historical limits, forcing treatment plants to design for wider conditions—and making digital planning essential for resilient infrastructure decisions.

• Analytics: A Referee For The Tug-Of-War Between MSC-EVs' Nature And Nurture

  Like a referee in a contest, advanced analytical methods are essential to mediate the push and pull of different factors influencing therapeutic efficacy.

• A Risk-Based Approach To Plasmid DNA And mRNA Process Development

  Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

• Controlling mAb Aggregates In Chromatography Process Development

  Antibody aggregation remains a critical downstream challenge, particularly for complex modalities. Explore why aggregates form, why they matter, and how chromatographic strategies can help reduce risk.

• Scope 3 Emissions: A Shared Challenge, A Collective Responsibility

  Despite growing sustainability efforts, our industry lags in climate goals, especially Scope 3 emissions. Discover why bold action and deep collaboration across the value chain are essential for real progress.

• Recent Updates To The Declaration Of Helsinki Affecting Clinical Trials

  The World Medical Association (WMA) has announced a significant, rare update to its cornerstone ethical document, the Declaration of Helsinki, which guides medical research involving human participants.